Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy.
Over the past year, data regarding 2 specific ovarian cancer management strategies have generated considerable interest within the clinical gynecologic cancer community among patients, clinicians, and re - searchers. One strategy involves the use of bevacizumab (Avastin), and the other approach centers on poly(ADPribose) polymerase (PARP) inhibitors.
ORLANDO—Women who are on intravenous (IV) chemotherapy regimens for recurrent ovarian carcinoma are at risk for nonadherence or nonpersistence with their treatment. But telephone support by an advanced practice nurse (APN) can lower this risk and even boost compliance, a new, nonrandomized study suggests.
Results 1 - 10 of 10